We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High-Risk Female Groups Screened for Fabry Disease

By LabMedica International staff writers
Posted on 26 Jun 2014
Print article
Image: The Applied Biosystem Veriti Thermal Cycler (Photo courtesy of Life Technologies).
Image: The Applied Biosystem Veriti Thermal Cycler (Photo courtesy of Life Technologies).
Although measurement of lysosomal α-galactosidase A (α-GAL) in women is not accurate for the diagnosis of Fabry disease (FD), determining the range of the enzyme activity presented by heterozygous females could become a valuable tool for minimizing the burden of screening by DNA sequencing all potential carriers.

This strategy would diminish the total number of sequencing reactions and, by consequence, greatly reduce the costs and the time needed for diagnosis, especially in those centers without high-throughput technologies, and can be implemented by establishing the range of enzyme in dried blood spots (DBS), plasma and leukocytes that suggests carrier status for FD.

Geneticists at the Universidade Federal do Rio Grande do Sul (Porto Alegre, Brazil) analyzed blood samples from 453 female patients with clinical suspicion of Fabry disease. Whole blood genomic DNA was extracted for genotyping and polymerase chain reactions were performed in a Veriti Thermal Cycler (Applied Biosystems, Foster City, CA, USA) and sequencing was done in Applied BioSystems’ ABI3500 genetic analyzer. Results of α-GAL activities in 377 DBS and/or 93 plasma and/or 88 leukocytes were obtained from patients' laboratory records.

From the 453 samples sequenced, 54 were heterozygous for pathogenic galactosidase, alpha (GLA) mutations. Thirteen previously described pathogenic mutations were found; most of them, in more than one patient. All patients carrying pathogenic mutations were called “heterozygotes” and those who do not were named as “controls”. The median α-GAL activity in DBS was 3.7 ± 3.2 nmol/h/mL in heterozygotes and 6.2 ± 3.5 nmol/h/mL in controls. In leukocytes and plasma heterozygote means were 23.9 ± 11.6 nmol/h/mg protein and 4.5 ± 2.5 nmol/h/mL, and control values were 41.6 ± 13.1 nmol/h/mg protein and 11.1 ± 5.4 nmol/h/mL, respectively.

Plasma and leukocyte activities presented high area under the curve (AUC) in receiver operating characteristic (ROC) curve analysis, both over 84%. When cutoffs were altered to identify all carriers, leukocyte specificity at 35.2% was higher than that of plasma at 27.6%. Moderated correlation and agreement coefficients were found between them, which reinforces the need for using both data combined.

The authors concluded that a combined approach involving plasma and leukocyte α-GAL activities, with distinct cutoffs for men and women, could represent a more accurate, faster and less expensive tool to screen women for FD in high-risk groups in middle- and low-income countries. Fabry disease (FD) is a rare X-linked inborn error of metabolism caused by deficient activity of lysosomal α-galactosidase A (α-GAL). Due to random X inactivation, α-GAL activity in heterozygous females ranges from very low to overlapping normal values. The study was published in the May 2014 issue of the journal Clinical Biochemistry.

Related Links:

Universidade Federal do Rio Grande do Sul
Applied Biosystems


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.